Skip to navigation Skip to content
  • The Cancer Letter on Facebook
  • The Cancer Letter on Twitter
  • The Cancer Letter on LinkedIn

The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
  • SUBSCRIBE
  • Login
  • SUBSCRIBE
  • Login
The Cancer Letter
Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
W. Kimryn Rathmell named CEO of The Ohio State James Cancer Hospital and Solove Research Institute
In Brief

W. Kimryn Rathmell named CEO of The Ohio State James Cancer Hospital and Solove Research Institute

April 25, 2025
Vol.51 No.16
In Brief

Siemens Healthineers, Ohio State Wexner Medical Center form 10-year, $105M partnership

December 06, 2024
Vol.50 No.45
Clinical Roundup

Ohio State completes first gene therapy for hemophilia B

December 06, 2024
Vol.50 No.45
In Brief

Paul Nurse receives 2024 Block Memorial Lectureship

October 04, 2024
Vol.50 No.37
In Brief

Christian Rolfo named director of Ohio State Division of Medical Oncology

June 21, 2024
Vol.50 No.25
Clinical Roundup

Lifileucel shrinks tumors in mNSCLC in phase II trial

May 10, 2024
Vol.50 No.19
In Brief

OSU—James Immunotherapy Management Clinic to focus on managing immune side effects and cancer control

April 12, 2024
Vol.50 No.15
In Brief

Nationwide Children’s Hospital and OSUCCC—James open proton therapy center opens

January 05, 2024
Vol.50 No.01
In Brief

Matthew Ringel, Electra Paskett, Zihai Li named deputy directors at OSUCCC

December 15, 2023
Vol.49 No.46
Clinical Roundup

Research finds dietary changes can reduce cancer-related fatigue

February 10, 2023
Vol.49 No.06

Posts navigation

Previous123Next

Trending Stories

  • Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel
  • FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
    “Patients are owed another review.”
  • Breakthrough Therapy designation, ASCO plenary, and NEJM publication notwithstanding, breast cancer drug camizestrant gets a No from ODAC
  • CDC’s recommendation to delay infant hepatitis B shot is likely to raise infections, JAMA studies show
  • CBER Director Vinay Prasad dared to “say no to drugs”
  • J. Craig Venter’s work was foundational to cancer advancement of the past 25 years

ABOUT
ABOUT
About The Cancer Letter
Accessibility Statement
Our Contributors
Editorial policies
Store
SUBSCRIPTIONS
SUBSCRIPTIONS
Our readers
Pricing
News alerts
About IP login
Job board
CONTACT
CONTACT
Contact us
Submission guidelines
Advertise
Careers
SEE ALSO
Cancer History Project
The Cancer Letter
Copyright © 2026 The Cancer Letter Inc. All rights reserved.
Privacy Policy
Terms & Conditions
FOLLOW US
Instagram
Twitter
LinkedIn
Facebook
Vimeo
Scroll to top
Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.
SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.
LOGINSUBSCRIBE NOW
SEARCH DATE
SEARCH TEXT
      Cancel
      OK
      Cancel
      OK
      Delete Account
      Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below
      No

      Never miss an issue!

      Get alerts for our award-winning coverage in your inbox.

      Login

       
      Forgot Password?

      Site license subscribers:
      Log in with your IP | Register a sponsored account